<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04620057</url>
  </required_header>
  <id_info>
    <org_study_id>29ES20</org_study_id>
    <nct_id>NCT04620057</nct_id>
  </id_info>
  <brief_title>Effects of Butyrate Against Pediatric Obesity</brief_title>
  <acronym>BAPO</acronym>
  <official_title>Effects of Oral Supplementation of Butyrate in Children With Obesity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federico II University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Federico II University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Worldwide obesity is a public health concern that is defined by the World Health Organization&#xD;
      as abnormal or excessive fat accumulation that may impair health. The main drivers of obesity&#xD;
      pathogenesis seem to be a long-term of energy discrepancy between too many calories consumed&#xD;
      and an increase of sedentary behavior. A growing body of evidence suggests that the set of&#xD;
      microbes that live within the digestive tract, making up the gut microbiota (GM), play a&#xD;
      metabolic role in energy regulation and substrate metabolism. Various factors can impact GM,&#xD;
      one of these are dietary compounds that deeply affect the growth and metabolism of gut&#xD;
      bacteria, since fermentation of nutrients is one core function of the intestinal microbes.&#xD;
      Among fermentation products an array of small organic metabolites are short-chain fatty acids&#xD;
      (SCFAs) acetate, propionate and butyrate. Among SCFAs, the C-4 fatty acid butyrate, the main&#xD;
      fuel for the colonocytes, might have a potential in alleviating obesity and related metabolic&#xD;
      complications. Butyrate could act as a regulator of body weight: a reasonable speculation is&#xD;
      that butyrate acts on components of the energy balance, promoting energy expenditure and/or&#xD;
      reducing energy intake. Preclinical studies have shown that butyrate supplementation prevent&#xD;
      high-fat diet-induced obesity and it is able to treat obesity. With the sharp increase of&#xD;
      obesity prevalence seen in the pediatric population, novel insights are necessary to&#xD;
      counteract this epidemic disease, the outcome of the study is to see whether oral butyrate&#xD;
      supplementation could exert similar effect in obese children.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 9, 2017</start_date>
  <completion_date type="Anticipated">January 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 11, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>BMI z-score change</measure>
    <time_frame>after 6 months from the start of intervention</time_frame>
    <description>BMI z-score change at least of ≥ 0.25</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>waist circumference</measure>
    <time_frame>after 6 months from the start of intervention</time_frame>
    <description>mean waist circumference change</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HOMA index change</measure>
    <time_frame>after 6 months from the start of intervention</time_frame>
    <description>mean of HOMA index change</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fasting glucose change</measure>
    <time_frame>after 6 months from the start of intervention</time_frame>
    <description>mean of fasting glucose change</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fasting insulin change</measure>
    <time_frame>after 6 months from the start of intervention</time_frame>
    <description>mean of fasting insulin change</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>total cholesterol change</measure>
    <time_frame>after 6 months from the start of intervention</time_frame>
    <description>mean of total cholesterol change</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Low density Lipoprotein cholesterol change</measure>
    <time_frame>after 6 months from the start of intervention</time_frame>
    <description>mean of Low density Lipoprotein cholesterol change</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High density Lipoprotein cholesterol change</measure>
    <time_frame>after 6 months from the start of intervention</time_frame>
    <description>mean of high density Lipoprotein cholesterol change</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma triglycerides change</measure>
    <time_frame>after 6 months from the start of intervention</time_frame>
    <description>mean of plasma triglycerides change</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>micro RNA 221- expression</measure>
    <time_frame>after 6 months from the start of intervention</time_frame>
    <description>mean of mir221- expression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum hormones</measure>
    <time_frame>after 6 months from the start of intervention</time_frame>
    <description>mean of serum hormones</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum adipokines</measure>
    <time_frame>after 6 months from the start of intervention</time_frame>
    <description>mean of serum adipokines</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>composition of the intestinal microbiota (metagenomics characteristics)</measure>
    <time_frame>after 6 months from the start of intervention</time_frame>
    <description>evaluation of gut microbiota structure by shotgun analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>composition of the metabolites of intestinal microbiota (metabolomics characteristics)</measure>
    <time_frame>after 6 months from the start of intervention</time_frame>
    <description>evaluation of gut microbiota function by gas-chromatography</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Obesity, Childhood</condition>
  <arm_group>
    <arm_group_label>Butyrate + standard care for pediatric obesity</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>standard care for pediatric obesity + sodium butyrate (20 mg/kg body weight/day)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo + standard care for pediatric obesity</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>standard care for pediatric obesity + placebo (cornstarch)</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>butyrate</intervention_name>
    <description>sodium butyrate (20 mg/kg body weight/day)</description>
    <arm_group_label>Butyrate + standard care for pediatric obesity</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>cornstarch</description>
    <arm_group_label>placebo + standard care for pediatric obesity</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Children/adolescents with diagnosis of obesity (BMI &gt;95° percentile for age and sex)&#xD;
             observed at Pediatric Section of Department of Translational Medical Sciences&#xD;
             (University of Naples Federico II)&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Age at enrollment &lt; 7 or &gt;16 years&#xD;
&#xD;
          -  BMI &lt;95° percentile for age and sex&#xD;
&#xD;
          -  Patients under pharmacological treatment for obesity (metformin)&#xD;
&#xD;
          -  Patients assuming vitamin E,&#xD;
&#xD;
          -  Patients assuming pre-, pro- or synbiotics&#xD;
&#xD;
          -  Simultaneous presence of other chronic diseases unrelated to obesity:&#xD;
&#xD;
               -  cancer,&#xD;
&#xD;
               -  immunodeficiency,&#xD;
&#xD;
               -  cystic fibrosis,&#xD;
&#xD;
               -  allergies,&#xD;
&#xD;
               -  celiac disease,&#xD;
&#xD;
               -  autoimmune diseases,&#xD;
&#xD;
               -  neuropsychiatric disorders,&#xD;
&#xD;
               -  type 1 diabetes,&#xD;
&#xD;
               -  inflammatory bowel diseases,&#xD;
&#xD;
               -  malformations of urinary or gastrointestinal or respiratory tract,&#xD;
&#xD;
               -  chronic lung diseases, genetic and metabolic diseases,&#xD;
&#xD;
               -  chronic hematological diseases.&#xD;
&#xD;
          -  History of surgery for the treatment of obesity&#xD;
&#xD;
          -  Any medical condition that may interfere with participation in this study&#xD;
&#xD;
          -  Participation in other clinical trials still in progress&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Naples Federico II</name>
      <address>
        <city>Naples</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roberto Berni Canani</last_name>
      <phone>0817462680</phone>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>October 26, 2020</study_first_submitted>
  <study_first_submitted_qc>November 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2020</study_first_posted>
  <last_update_submitted>November 3, 2020</last_update_submitted>
  <last_update_submitted_qc>November 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Federico II University</investigator_affiliation>
    <investigator_full_name>Roberto Berni Canani</investigator_full_name>
    <investigator_title>Chief of the Pediatric Allergy Program at the Department of Translational Medical Science Chief of the ImmunoNutritionLab at CEINGE - Advanced Biotechnologies</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Pediatric Obesity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

